FDA Approves Treatment for Bone Marrow Disorder
Posted on: Thursday, 4 May 2006, 12:03 CDT
The FDA has approved MGI Pharma and SuperGen's Dacogen for injection for the treatment of myelodysplastic syndromes, a bone marrow disorder which can lead to leukemia.
Now that the FDA has given its approval for the drug, MGI Pharma will waste no time in making it available to patients with a commercial launch expected during the second quarter of 2006.
"The FDA approval of Dacogen marks an important advancement for patients who suffer from MDS," said Dr John Bennett, chair of The Myelodysplastic Syndromes Foundation. "Patients with this serious condition are often anemic, experience fatigue and weakness and, in certain cases with an increase in leukemic blast cells, MDS can result in bone marrow failure."
Results from a phase III clinical trial demonstrated an overall response rate of 21% in Dacogen-treated patients considered evaluable for response, defined as those patients with pathologically confirmed MDS at baseline who received at least 2 cycles of treatment, compared to 0% in the supportive care arm.
Lonnie Moulder, president and CEO of MGI added that the company continues to develop the drug in different indications, including acute myeloid leukemia, chronic myelogenous leukemia, and solid tumors.
Source: Datamonitor
Related Articles
- FDA Accepts sNDA for Alternative Dosing Regimen for Dacogen(R) (decitabine for injection) to Treat Patients with Myelodysplastic Syndromes (MDS)
- Pharmion Presents Clinical Data Demonstrating Significant Survival Advantage of Vidaza(R) in Patients With Myelodysplastic Syndromes (MDS)
- Gene Mutations Predict Treatment Outcomes in Patients With Leukemia [Abstract #4]
- ZIOPHARM Announces Preliminary ZIO-101 Phase I Leukemia Data; Encouraging Signs of Clinical Activity in Patients With Leukemia
- Statewide Blood Bank to Collect Umbilical Cord Blood: More Doctors Using Cord Stem Cells to Treat Patients With Leukemia
- Advances in Radiotherapy Show Benefit for High-Risk Elderly Patients With Leukemia and Non-Hodgkin Lymphoma
- Updated Interim Aranesp(R) Phase 2 Data Suggest Major Response in Anemic Patients With Myelodysplastic Syndrome (MDS); Patients With Bone Marrow Disorder Also Showed Improvements in Hemoglobin Levels and Fatigue
- Interim Data Suggest Major Response With Aranesp(R) in Anemic Patients With Myelodysplastic Syndromes (MDS)
- TRISENOX(R) Produces Hematologic Responses in 30 Percent of Patients With Higher-Risk MDS
- FDA Advisory Committee Recommends Accelerated Clofarabine Approval for Most Common Pediatric Leukemia; FDA to Make Approval Decision By End of Year
 |
 |
User Comments (0)
RSS Feeds